Accelerated Alzheimer's Disease Model via Tau Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Alzheimer's disease animal models, such as the APP/PS1 mouse model, fail to exhibit neuron loss and neurofibrillary tangles in a timely manner, delaying cognitive impairment studies and increasing maintenance costs, as they require over a year to develop significant pathology.
Innovation Solution
Injecting a human mutant tau protein expression vector and adenovirus into APP/PS1 mice to accelerate Aβ pathology and astrogliosis, resulting in an animal model that exhibits Alzheimer's disease features by 8 months, including tau pathology and cognitive deficits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If APP/PS1 mouse model is used to study Alzheimer's disease, then Aβ plaque pathology can be observed, but neuron loss and neurofibrillary tangles do not appear for over one year
Solution Approach 1:
The patent applies preliminary action by pre-introducing human mutant tau protein (P301L) expression construct into APP/PS1 mice before the natural disease progression. This pre-preparation of tau protein expression capability allows the mice to rapidly develop neurofibrillary tangles and neuron loss when combined with adenovirus-induced astrogliosis, eliminating the need to wait over a year for these pathological features to naturally appear.
Solution Approach 2:
The patent changes the biological parameter of tau protein expression by introducing human mutant tau (P301L) which has altered properties compared to endogenous mouse tau. This parameter change enables accelerated formation of neurofibrillary tangles and neuron loss, compressing the pathological development timeline from over one year to approximately 8 months while maintaining pathological reliability.
2Reliability
If APP/PS1 mice are maintained for one year or more to observe neurodegeneration, then complete AD pathology can be studied, but maintenance costs increase significantly
Solution Approach 1:
By pre-introducing the human mutant tau protein expression system into APP/PS1 mice, the patent creates a primed model that will rapidly exhibit complete AD pathology including neuron loss and neurofibrillary tangles within 8 months. This preliminary preparation eliminates the need for long-term expensive maintenance while ensuring all critical pathological features are present for study.
Solution Approach 2:
The introduction of human mutant tau protein (P301L) changes the temporal parameter of pathological development, accelerating the appearance of neuron loss and neurofibrillary tangles. This parameter modification reduces the maintenance period from over one year to 8 months, significantly reducing associated costs while preserving pathological completeness.
3Reliability
If APP/PS1 mouse model is used, then Aβ overproduction pathology is exhibited, but cognitive impairment and memory deficit are not clearly observed
Solution Approach 1:
The patent applies preliminary action by pre-equipping APP/PS1 mice with human mutant tau protein expression capability and then inducing astrogliosis with adenovirus. This sequential preliminary preparation ensures that when the mice reach 8 months, they exhibit not only Aβ pathology but also neurofibrillary tangles, neuron loss, and clear cognitive impairment, enabling accurate measurement of memory deficit and cognitive dysfunction.
Solution Approach 2:
The patent creates a composite disease model by combining APP/PS1 transgenic background with human mutant tau protein expression and adenovirus-induced astrogliosis. This composite approach integrates multiple pathological mechanisms (Aβ deposition, tau aggregation, astrocyte activation) to produce a more complete and measurable cognitive impairment phenotype while preserving accurate Aβ pathology characteristics.
Data Source
AI summary
The present invention relates to a preparation method for an animal model with Alzheimer's disease by injecting a human mutant tau (AAV-hTau) vector and adenovirus into an animal. The preparation method for an AD animal model provided by the present invention may contribute to the development of the field of treatment technology for treating AD since the preparation method causes AD pathology to appear as early as 8 months old and facilitates studies on AD target treatment strategies and tau pathology.